Estrogenic effects of physiological concentrations of 5-androstene-3 beta, 17 beta-diol and its metabolism in MCF7 human breast cancer cells
- PMID: 6458355
Estrogenic effects of physiological concentrations of 5-androstene-3 beta, 17 beta-diol and its metabolism in MCF7 human breast cancer cells
Abstract
5-Androstene-3 beta, 17 beta-diol (ADIOL) has previously been shown to have a high affinity for the estrogen receptor and to translocate it to the nucleus in vitro and in vivo. This compound and related C19 delta 5-steroids of adrenal origin have now been examined for their ability to induce the synthesis in MCF7 cells of an estrogen-dependent secreted glycoprotein (M.W. 46,000). Concentrations required for half-maximum induction were 2 nM for ADIOL and 500 nM for dehydroepiandrosterone (DHEA). Dehydroepiandrosterone sulfate showed weak inducing ability at concentrations of 1 microM or greater. The induction by ADIOL was unaffected by the presence of an aromatase inhibitor, and 5 alpha-androstane-3 beta, 17 beta-diol, which cannot be aromatized, also induced the M.W. 46,000 protein at low concentrations. When cells were exposed to 10 nM [3H]ADIOL, the cytosol and nuclear fractions contained [3H]ADIOL resistant to charcoal adsorption. The bound [3H]ADIOL in the cytosol and nucleus was displaceable by 17 beta-estradiol and tamoxifen, suggesting that it was binding to the estrogen receptor. [3H]ADIOL was metabolized to its 3 beta-sulfate, which was excreted into the medium, and to [3H]DHEA, which was found in the cells and the medium as free DHEA and its 3 beta-sulfate. [3H]DHEA was also metabolized by the cells to its 3 beta-sulfate, to free ADIOL, and to the 3 beta-sulfate of adiol. We conclude that: (a) ADIOL is effective as an estrogen in MCF7 cells at a concentration of 2 nM, which is within the range found in the blood of normal women; and (b) sulfurylation is a major route of inactivation of 3 beta-hydroxy delta 5-steroids in MCF7 cells.
Similar articles
-
Stimulation of cell proliferation and estrogenic response by adrenal C19-delta 5-steroids in the ZR-75-1 human breast cancer cell line.Cancer Res. 1986 Oct;46(10):4933-7. Cancer Res. 1986. PMID: 2944574
-
Dehydroepiandrosterone and androst-5-ene-3 beta,17 beta-diol in human mammary cancer cytosolic and nuclear compartments and their relationship to estrogen receptor.Cancer Res. 1980 Oct;40(10):3815-20. Cancer Res. 1980. PMID: 6449285
-
Influence of dehydroepiandrosterone and 5-en-androstene-3 beta, 17 beta-diol on the growth of MCF-7 human breast cancer cells induced by 17 beta-estradiol.Anticancer Res. 1992 May-Jun;12(3):799-803. Anticancer Res. 1992. PMID: 1535770
-
Role of metabolism in the activation of dehydroepiandrosterone as a peroxisome proliferator.J Endocrinol. 1996 Sep;150 Suppl:S129-47. J Endocrinol. 1996. PMID: 8943797 Review.
-
Physiological importance of dehydroepiandrosterone.Lancet. 1994 Jun 11;343(8911):1479-81. doi: 10.1016/s0140-6736(94)92587-9. Lancet. 1994. PMID: 7911183 Review.
Cited by
-
Androstenedione and androst-5-ene-3 beta,17 beta-diol stimulate DMBA-induced rat mammary tumors--role of aromatase.Breast Cancer Res Treat. 1989 Jan;13(1):61-9. doi: 10.1007/BF01806551. Breast Cancer Res Treat. 1989. PMID: 2495831
-
Differential induction of androgen receptor transactivation by different androgen receptor coactivators in human prostate cancer DU145 cells.Endocrine. 1999 Oct;11(2):195-202. doi: 10.1385/endo:11:2:195. Endocrine. 1999. PMID: 10709768
-
5-En-androstene-3 beta,17 beta-diol inhibits the growth of MCF-7 breast cancer cells when oestrogen receptors are blocked by oestradiol.Br J Cancer. 1994 Dec;70(6):1035-9. doi: 10.1038/bjc.1994.444. Br J Cancer. 1994. PMID: 7981051 Free PMC article.
-
Synergistic control of sex hormones by 17β-HSD type 7: a novel target for estrogen-dependent breast cancer.J Mol Cell Biol. 2015 Dec;7(6):568-79. doi: 10.1093/jmcb/mjv028. Epub 2015 May 12. J Mol Cell Biol. 2015. PMID: 25966904 Free PMC article.
-
IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients.Breast Cancer Res Treat. 2017 Sep;165(2):343-353. doi: 10.1007/s10549-017-4328-z. Epub 2017 Jun 13. Breast Cancer Res Treat. 2017. PMID: 28612226 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical